A study conducted on a transgenic mouse model of AD reported that the antisense oligonucleotide (ASO) of microRNA-485-3p decreased the development of tau pathology, Aβ plaque accumulation, neuroinflammation, and cognitive decline [142]. This evidence concerns the gene MAPT and Alzheimer disease.